Netherlands· NL-baa8a37ca3b5

Depo-Provera 150, suspensie voor injectie 150 mg/ml

A medroxyprogesterone product containing medroxyprogesteronacetaat, registered in Netherlands by Pfizer B.V.. The same ATC class is registered in 11 of our 19 countries.

ATC G03AC06

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about medroxyprogesteronacetaatAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Medroxyprogesterone is registered in 11 of 19 countries.

Countries holding a registration under ATC G03AC06 (medroxyprogesterone), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
7 of them publish a price we can compare per daily dose

Search medroxyprogesterone products by name

Medroxyprogesterone · ATC G03AC06

11 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Icelandprice
Ireland
Netherlands
Norwayprice
Polandprice
Switzerlandprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)

Active substance: MEDROXYPROGESTERONACETAAT
Manufacturer: Pfizer B.V.
Country: Netherlands (NL)
ATC code: G03AC06
ATC class: Medroxyprogesterone
Defined daily dose: 1.67 mg, P
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
06602

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

245 interactions on record for medroxyprogesterone.

Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check medroxyprogesterone against other medicines How interaction checks work

Medroxyprogesterone · interactions on record

245 records

21 severe
213 moderate
7 minor

Most severe, free to view

Tranexamic acidB02AA02severe
BosentanC02KX01severe
GriseofulvinD01AA08severe
GriseofulvinD01BA01severe

4 more interactions with mechanism and management, from a commercially licensed source.

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Medroxyprogesterone in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All medroxyprogesterone products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

Austria · Depocon, Farlutal
Belgium · Depo-Provera, Provera
Bulgaria · Фарлутал
Czechia · Depo-Provera, Provera
Germany · Depo-Clinovir, Mpa
Denmark · Depo-Provera, Provera
Estonia · Farlutal
Spain · Depo-Progevera, Progevera
Finland · Farlutal, Provera
France · Depo Prodasone, Depo Provera
United Kingdom (Northern Ireland) · Depo-Provera, Medroxyprogesterone Acetate Pfizer
Croatia · Provera
Hungary · Depo-Provera, Provera
Ireland · Depo-Provera, Provera
Iceland · Depo-Provera
Italy · Depo-Provera, Farlutal
Luxembourg · Depo-Provera, Provera
Latvia · Depo-Provera
Norway · Depo-Provera, Provera
Poland · Depo-Provera, Provera
Portugal · Depo-Provera 150
Sweden · Depo-Provera, Provera

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/0943268f-6fb2-4ed3-80c0-990a123eab4a
GET /v1/drugs/0943268f-6fb2-4ed3-80c0-990a123eab4a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Suspensie voor injectie",
  "route": "Intramusculair gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h06602_smpc.pdf",
  "strength": null,
  "atc_label": "Medroxyprogesterone",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg06602",
  "excipients": [
    "MACROGOL 3350",
    "METHYLPARAHYDROXYBENZOAAT (E 218)",
    "NATRIUMCHLORIDE",
    "NATRIUMHYDROXIDE (E 524)",
    "POLYSORBAAT 80 (E 433)",
    "PROPYLPARAHYDROXYBENZOAAT",
    "WATER VOOR INJECTIE",
    "ZOUTZUUR (E 507)"
  ],
  "substances": [
    "MEDROXYPROGESTERONACETAAT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h06602.pdf",
  "authorised_at": "1973/04/04",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "06602",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about medroxyprogesterone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console